Insmed stock surges on Phase 3 trial win (NASDAQ:INSM)
Insmed stock surges over 120% as its oral candidate for bronchiectasis reaches Phase 3 trial goals. The company plans to file FDA application in Q4 2024. Read more here.
Source: seekingalpha.com